clinical trials

Recent Rosacea Blog Posts

Thanks to a comment from Sophie on the post rosacea and doxium (calcium dobesilate) we know that Dr. Cuevas who is responsible for several papers on Dobesilate, is accepting people to try it as a treatment for rosacea. Thanks for the info Sophie. Calcium dobesilate (2,5-dihydroxybenzene sulfonate) is a vasoactive drug with presumed effects on […]

Continue Reading

The Clinical Trials register has listed a new trial for papulopustular rosacea. The trial, sponsored by Intendis, the manufacturer of Finacea, wants to compare the combination of Oracea and Finacea, with the combination of Oracea and Metrogel 1%. It seems clear from this that Intendis would like to position Finacea as a viable alternative to […]

Continue Reading

Medicis readies to trial Ziana for rosacea

Just posted on the clinicaltrials.gov database is an entry “Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea”. This topical product, known as Ziana, is currently approved for the treatment of acne. Ziana is manufactured by Medicis who also make Plexion and Solodyn. The combination of tretinoin and clindamycin […]

Continue Reading

The Clinical Trial register is showing details for the bio-availabilty trial for COL-118/Sansrosa. This Phase 2 trial aims to compare the amount of the active ingredient that is bio-available when the newly formulated gel is used on rosacea skin, and when used as eye drops. This announcement appears to be the extra trial asked for […]

Continue Reading

In November 2006 I blogged about taking part in some research at Murdoch University investigating the relationship between stress and the flushing of rosacea. Recently the researcher, Daphne Su, has thanked the trial participants by circulating a summary document. The research has been written up as a thesis so this summary was a short description […]

Continue Reading

 

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.